机器学习引导的下一代癌症疗法工程化研究博士研究员
PhD Studentship: Machine Learning-Guided Engineering of Next-Generation Cancer Therapeutics
原帖优先:申请材料、截止时间与资格以原帖和学校官方说明为准。
AI 中文速览
- 研究内容
- 本项目旨在开发能够更有效穿透实体瘤的小型、高效抗体片段,学生将采用最先进的机器学习方法设计新型抗体片段,并在大肠杆菌中表达、纯化和进行详细的生化与生物物理表征。研究结合了化学、生物学和人工智能,利用合成生物学方法引入非规范氨基酸以改善靶向性和治疗性能。
- 申请条件
- 申请者需在生物科学、生物化学、化学生物学、化学及相关领域取得标准最低2:1的学位,具备高度的积极性,并对将计算与实验方法应用于癌症治疗挑战充满热情。
- 待遇
- 资助涵盖英国本地(Home)学费以及为期3年的每年生活津贴。当前UEA/机构博士生活津贴标准为每年20,409英镑,并将根据2027/28年度商定的通货膨胀率进行上调。
- 申请方式
- 原文未说明具体的申请方式、提交语言或在线网申地址。
由 gemini-2.5-flash-lite 生成,博士岗判定置信度 100%。
岗位信息
- 截止
- (Europe/London) 剩 93 天
- 学科
- 生物化学、遗传与分子生物学
- 合同类型
- 雇佣合同
- 原文薪资
- GBP 20,409 / 年(税前)
- 税后月薪(估)
- ¥12,800;房租后 ¥4,500
- 估算假设
- 单身、无子女、雇佣合同的粗略估算,以学校 offer 为准;扣除率 18%;汇率日期 2026-10-01
- 原帖发布
- 本站收录
- 内容更新
- 原帖导师候选(待核验)
- Dr Amit Sachdeva
- 来源
- jobs.ac.uk(英国博士项目及学术招聘) · 最近核对 2026-11-22
- 详情核验
判定依据(原文摘录)
- 资金仅限英国本地申请者并包含生活津贴
Funding is available to UK applicants and comprises ‘home’ tuition fees and an annual stipend for 3 years.
- 导师为Dr Amit Sachdeva
Primary Supervisor - Dr Amit Sachdeva
原文
Primary Supervisor - Dr Amit Sachdeva
Monoclonal antibodies have transformed the treatment of cancer by selectively recognising tumour-associated receptors and triggering cellular responses that lead to cancer cell death. Despite their clinical success, conventional full-length antibodies often show limited effectiveness against solid tumours because their large molecular size restricts deep penetration into tumour tissue. Overcoming this challenge represents a major opportunity in the development of next generation cancer therapeutics.
This interdisciplinary PhD project aims to develop small, highly effective antibody fragments capable of penetrating solid tumours more efficiently than conventional antibodies. The student will employ state-of-the-art machine learning approaches to design novel antibody fragments. These computationally engineered molecules will then be expressed in Escherichia coli . The project will involve cloning, expression and purification of engineered antibody fragments, followed by detailed biochemical and biophysical characterisation. Their binding affinity to the target will be evaluated on cancer cell lines, using our previously developed methods. Furthermore, the most promising candidates will be equipped with non-canonical amino acids through synthetic biology approaches, enabling the introduction of new chemical functionalities to improve targeting, and therapeutic performance.
Working at the interface of chemistry, biology, and artificial intelligence, the successful candidate will gain extensive training in cutting-edge methodologies including machine learning-guided protein design, molecular cloning, recombinant protein expression, protein purification, cell-based assays, gel electrophoresis, Western blotting and chemical protein modification techniques. The project offers a unique opportunity to contribute to the development of next-generation biologic medicines while acquiring a highly sought-after multidisciplinary skillset spanning chemical biology, synthetic biology, biotechnology, and cancer research.
This PhD is ideally suited to a highly motivated student in biochemistry, chemistry, molecular biology, biotechnology, or a related discipline who is excited by the prospect of applying computational and experimental approaches to address pressing challenges in cancer therapy.
Entry Requirements
The standard minimum entry requirement is 2:1 in Biological Sciences, Biochemistry, Chemical Biology, Chemistry, and related fields.
Mode of Study
Full-time
Start Date
1 October 2027
Additional Funding Information
This PhD project is in a competition for a Faculty of Science funded studentship. Funding is available to UK applicants and comprises ‘home’ tuition fees and an annual stipend for 3 years. The current UEA / institutional PhD stipend rate is £20,409 and will be subject to any agreed inflationary uplift for 2027/28.